The European Prevention of Alzheimer’s Dementia Consortium (EPAD) is a unique and ground-breaking European initiative to streamline the testing and development of preventative treatments for Alzheimer’s disease. The EPAD project was part of the Innovative Medicines Initiative (IMI), a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA. EPAD funding from IMI came to an end in October 2020. It was the largest ever public-private partnership in Alzheimer’s disease research, combining knowledge and expertise from 39 organizations across multiple sectors.
To access the data, users will need to make an online request via the Alzheimer’s Disease Workbench of the Alzheimer’s Disease Data Initiative (ADDI).
View Resource